# Anthony Bewley

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/anthony-bewley/

## Facts

| Field | Value |
| --- | --- |
| Citations | 5,746 |
| Field | Dermatology and Skin Diseases |
| h-index | 38 |
| i10-index | 129 |
| Last Known Institution | Queen Mary University of London |
| OpenAlex ID | https://openalex.org/A5072258821 |
| ORCID iD | 0000-0003-1195-0290 |
| Works | 307 |

## Researcher papers

- [Updating the diagnosis, classification and assessment of rosacea: recommendations from the global <scp>ROS</scp> acea <scp>CO</scp> nsensus ( <scp>ROSCO</scp> ) panel](https://scholariq.org/papers/updating-the-diagnosis-classification-and-assessment-of-rosacea-recommendations/)
- [Recommendations for rosacea diagnosis, classification and management: update from the global <scp>ROS</scp> acea <scp>CO</scp> nsensus 2019 panel](https://scholariq.org/papers/recommendations-for-rosacea-diagnosis-classification-and-management-update-from/)
- [Assessment of Accuracy of an Artificial Intelligence Algorithm to Detect Melanoma in Images of Skin Lesions](https://scholariq.org/papers/assessment-of-accuracy-of-an-artificial-intelligence-algorithm-to-detect/)
- [The efficacy and safety of apremilast, etanercept and placebo in patients with moderate‐to‐severe plaque psoriasis: 52‐week results from a phase IIIb, randomized, placebo‐controlled trial (LIBERATE)](https://scholariq.org/papers/the-efficacy-and-safety-of-apremilast-etanercept-and-placebo-in-patients-with/)
- [Factors associated with adverse COVID-19 outcomes in patients with psoriasis—insights from a global registry–based study](https://scholariq.org/papers/factors-associated-with-adverse-covid-19-outcomes-in-patients-with-psoriasis/)
- [Rosacea treatment update: recommendations from the global <scp>ROS</scp> acea <scp>CO</scp> nsensus ( <scp>ROSCO</scp> ) panel](https://scholariq.org/papers/rosacea-treatment-update-recommendations-from-the-global-scp-ros-scp-acea-scp-co/)
- [Maximizing patient adherence for optimal outcomes in psoriasis](https://scholariq.org/papers/maximizing-patient-adherence-for-optimal-outcomes-in-psoriasis/)
- [Drug Survival Associated With Effectiveness and Safety of Treatment With Guselkumab, Ixekizumab, Secukinumab, Ustekinumab, and Adalimumab in Patients With Psoriasis](https://scholariq.org/papers/drug-survival-associated-with-effectiveness-and-safety-of-treatment-with/)
- [Efficacy and Safety of Tralokinumab in Adolescents With Moderate to Severe Atopic Dermatitis](https://scholariq.org/papers/efficacy-and-safety-of-tralokinumab-in-adolescents-with-moderate-to-severe/)
- [Identifying individual psychosocial and adherence support needs in patients with psoriasis: a multinational two‐stage qualitative and quantitative study](https://scholariq.org/papers/identifying-individual-psychosocial-and-adherence-support-needs-in-patients-with/)
- [A Real-World Data Study on the Healthcare Resource Use for Uncontrolled Moderate-to-Severe Atopic Dermatitis in Secondary Care in the United Kingdom Prior to the Introduction of Biologic Treatment](https://scholariq.org/papers/a-real-world-data-study-on-the-healthcare-resource-use-for-uncontrolled-moderate/)

## Researcher topics

- [Dermatology and Skin Diseases](https://scholariq.org/topics/dermatology-and-skin-diseases/)
- [Psoriasis: Treatment and Pathogenesis](https://scholariq.org/topics/psoriasis-treatment-and-pathogenesis/)
- [Body Image and Dysmorphia Studies](https://scholariq.org/topics/body-image-and-dysmorphia-studies/)
- [Spondyloarthritis Studies and Treatments](https://scholariq.org/topics/spondyloarthritis-studies-and-treatments/)
- [Acne and Rosacea Treatments and Effects](https://scholariq.org/topics/acne-and-rosacea-treatments-and-effects/)

## Researcher university

- [Queen Mary University of London](https://scholariq.org/institutions/queen-mary-university-of-london/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.